Payment overview · 2025
General Payments
$140.75
7 reported records · 5 companies
Healthcare provider profile · identity verified
James M Bachstein, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEBANON, TN · NPI 1104802271
Verified facts
What the public records show
CMS Open Payments records show James M Bachstein, MD received $140.75 in general payments during 2025 across 7 reported records.
Aimmune Therapeutics, Inc. accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.00 | 37.7% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $29.35 | 20.9% | 1 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $21.94 | 15.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.48 | 15.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.98 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.75 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $53.00 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 446 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 102 |
| Lisinopril | Lisinopril | 374 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 62 |
| Omeprazole | Omeprazole | 203 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 88 |
| Metformin Hcl Er | Metformin Hcl | 173 | 53 |
| Losartan Potassium | Losartan Potassium | 169 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 42 |
| Furosemide | Furosemide | 167 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 40 |
| Simvastatin | Simvastatin | 147 | 42 |
| Trazodone Hcl | Trazodone Hcl | 136 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 41 |
| Famotidine | Famotidine | 116 | 42 |
| Gabapentin | Gabapentin | 112 | 40 |
| Allopurinol | Allopurinol | 111 | 28 |
| Azelastine Hcl | Azelastine Hcl | 111 | 49 |
| Carvedilol | Carvedilol | 111 | 30 |
| Finasteride | Finasteride | 110 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 31 |
| Meloxicam | Meloxicam | 110 | 35 |
| Atenolol | Atenolol | 109 | 32 |
| Sertraline Hcl | Sertraline Hcl | 107 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 24 |
| Chlorthalidone | Chlorthalidone | 82 | 28 |
| Montelukast Sodium | Montelukast Sodium | 80 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 20 |
| Eliquis | Apixaban | 72 | 21 |
| Irbesartan | Irbesartan | 72 | 18 |
| Mirtazapine | Mirtazapine | 71 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 28 |
| Alprazolam | Alprazolam | 70 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 19 |
| Potassium Chloride | Potassium Chloride | 69 | 19 |
| Synthroid | Levothyroxine Sodium | 68 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 18 |
| Glimepiride | Glimepiride | 65 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 65 | 22 |
| Glipizide | Glipizide | 64 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 11 |
| Farxiga | Dapagliflozin Propanediol | 55 | 16 |
| Lorazepam | Lorazepam | 54 | suppressed |
| Nifedipine Er | Nifedipine | 54 | 14 |
| Metformin Hcl | Metformin Hcl | 53 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 28 |
| Ozempic | Semaglutide | 52 | 12 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Cephalexin | Cephalexin | 47 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 45 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 15 |
| Baclofen | Baclofen | 44 | 14 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 12 |
| Ezetimibe | Ezetimibe | 41 | 11 |
| Nystatin | Nystatin | 41 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Linzess | Linaclotide | 37 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Methylprednisolone | Methylprednisolone | 37 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 36 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | 13 |
| Candesartan Cilexetil | Candesartan Cilexetil | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Ramelteon | Ramelteon | 30 | 13 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Estradiol | Estradiol | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 23 |
| Valsartan | Valsartan | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 21 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 19 |
| Lactulose | Lactulose | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 14 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Naproxen | Naproxen | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 14 |
| Indapamide | Indapamide | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Spironolactone | Spironolactone | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.75 · 7 records | Aimmune Therapeutics, Inc. | ENTYVIO, REZDIFFRA, Sucraid, VOQUEZNA, ZENPEP | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error